Financiado en parte por Baxter International, Baxter Healthcare Corporation, Baxter
Essential fatty acid deficiency, olive oil-based intravenous lipid emulsion, and genetic polymorphisms: A pediatric randomized controlled trial
Blanco C, Chang W, Bhatt AJ, Gerday E, Talati AJ, Dereddy N, Singh R, Ryan E, Senterre T
Journal of pediatric gastroenterology and nutrition · 3 citas
Etiquetas de revisión
Vínculos de autores con la industriaFinanciado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Baxter International
- Empresa
- Baxter Healthcare Corporation
- Empresa
- Baxter
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-05-25 · J Pediatr Gastroenterol Nutr · vol. 81 · número 2 · págs. 314–323
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 2 citas · más que el 75% de estudios similares · 1.1× el promedio de su campo
- Referencias
- 36 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC
- Áreas de investigación
- Clinical Nutrition and Gastroenterology · Fatty Acid Research and Health · Lipid metabolism and biosynthesis
- Palabras clave
- essential fatty acid deficiency, soybean oil, parenteral nutrition, preterm infants, plasma fatty acid profile, arachidonic acid, linoleic acid, Mead acid, triene/tetraene ratio, pediatric patients
- MeSH
- humans, fatty acid desaturases, soybean oil, fat emulsions, intravenous, arachidonic acid, fatty acids, essential, linoleic acid, parenteral nutrition, double-blind method, polymorphism, genetic, child, preschool, infant, infant, newborn, infant, premature, female, male, olive oil
9 autores
- Cynthia Liudmilla Blanco🇺🇸 · autor de correspondenciaThe University of Texas at San Antonio Health Science Center
- Weili Chang🇺🇸East Carolina University
- Abhay Bhatt🇺🇸University of Mississippi Medical Center
- Erick B. Gerday🇺🇸Utah Valley Regional Medical Center
- Ajay J. Talati🇺🇸University of Tennessee Health Science Center
- Narendra Reddy Dereddy🇺🇸AdventHealth Orlando; AdventHealth for Children
- Rachana Singh🇺🇸Tufts University
- Erika Ryan🇺🇸Baxter (United States)
- Thibault Senterre🇧🇪🇺🇸University of Liège; Baxter (United States)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
There is a concern that decreasing soybean oil (SO) content in intravenous lipid emulsions (ILEs) may increase the risk for essential fatty acid deficiency (EFAD). This study evaluates the risk of EFAD in pediatric patients who were expected to require parenteral nutrition for at least 7 days with an 80% olive oil/20% SO ILE (OO/SO group) versus a 100% SO ILE (SO group).
Methods
This randomized, double-blind, controlled, multicenter study evaluated 101 pediatric patients including 94 preterm infants. The primary outcome was the incidence of EFAD, including the analysis of the plasma fatty acid (FA) profiles and genetic polymorphism in the FA desaturase genes in patients with extreme arachidonic acid values.
Results
Treatment duration was 10.3 ± 7.8 and 11.3 ± 9.4 days in the OO/SO and SO groups respectively. No EFAD was observed. Linoleic acid values increased in both groups but to a lesser extent in the OO/SO group. Arachidonic acid values remained stable within the two groups. The changes in mead acid value were opposite in the two groups, demonstrating an increase in the OO/SO group and a decrease in the SO group, leading to similar changes in the triene:tetraene ratio (T:T). Genetic polymorphisms were frequently observed in patients presenting extreme arachidonic acid values in both groups.
Conclusions
The use of an 80% OO/20% SO ILE is well tolerated, safe, and does not increase the risk of EFAD in pediatric patients. The assessment of EFAD should not only consider the T:T but also the complete FA profile and genetic polymorphisms.
Trial identification number
Trial Identification Number and URL: NCT04555044, https://clinicaltrials.gov/study/NCT04555044?term=NCT04555044&rank=1.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.